Reversibility of Arctic Sea Ice Retreat - A Multi-Scale Modeling Approach

Arctic summer sea ice has been retreating rapidly over past decade. Climate model projections show further retreat under typical forcing scenarios. The mode of the retreat is a matter of debate. Low-order models show reversible and irreversible retreat depending on the shape of the albedo parametrization. Climate models do not show irreversible sea ice losses, but generally underestimate the current trend of retreat

The Value of Energy Efficiency in the Anchorage Residential Property Market

The residential sector is a significant source of carbon dioxide emissions. Improving the energy efficiency of the housing stock can reduce carbon emissions and increase property values. In this paper, we examine whether residential energy efficiency improvements are capitalized into home prices in Anchorage, Alaska. The impact of a residential energy efficiency program on single-family house prices is estimated using both a hedonic pricing framework and a difference-in- differences estimator. The results indicate that participating homes sell for a premium of 4.2% compared to similar properties that did not participate in the program

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.

Item does not contain fulltextInterleukin-1 (IL-1) is a highly active pro-inflammatory cytokine that lowers pain thresholds and damages tissues. Monotherapy blocking IL-1 activity in autoinflammatory syndromes results in a rapid and sustained reduction in disease severity, including reversal of inflammation-mediated loss of sight, hearing and organ function. This approach can therefore be effective in treating common conditions such as post-infarction heart failure, and trials targeting a broad spectrum of new indications are underway. So far, three IL-1-targeted agents have been approved: the IL-1 receptor antagonist anakinra, the soluble decoy receptor rilonacept and the neutralizing monoclonal anti-IL-1beta antibody canakinumab. In addition, a monoclonal antibody directed against the IL-1 receptor and a neutralizing anti-IL-1alpha antibody are in clinical trials